人单核RNA测序揭示CD47为多柔比星心肌病治疗靶点
研究对多柔比星心肌病(DoxCM)、非缺血性心肌病及非衰竭供体的左心室心肌行单核RNA测序,发现DoxCM中POSTN+活化成纤维细胞增多、吞噬相关基因下调及抗吞噬分子CD47表达升高。小鼠实验显示CD47抗体中和可预防并治疗多柔比星所致左室射血分数下降和纤维化,该保护作用依赖常驻心脏巨噬细胞。
要点
- DoxCM心肌中POSTN+活化成纤维细胞增多且CD47表达上调
- CD47抗体中和可预防并治疗多柔比星所致左室射血分数下降和纤维化
- CD47中和的心肌保护作用依赖常驻心脏巨噬细胞对成纤维细胞的清除
核心结论
- CD47是多柔比星心肌病的疾病特异性靶点,有望用于减轻其心脏功能障碍。
研究设计与样本
- 对人DoxCM、非缺血性心肌病及非衰竭供体的左心室心肌组织行单核RNA测序。
- 结合免疫染色、流式细胞术、抗体中和及细胞清除研究验证发现并明确体内机制。
主要发现
- DoxCM左心室心肌较非衰竭供体和非缺血性心肌病患者POSTN+活化成纤维细胞增多。
- DoxCM中吞噬相关基因下调、抗吞噬分子CD47表达升高。
- 人心脏切片免疫染色和小鼠研究显示DoxCM及小鼠乳腺癌模型中POSTN+细胞和CD47增加。
- CD47抗体中和可预防并治疗多柔比星所致左室射血分数下降和纤维化。
- 清除常驻心脏巨噬细胞可阻断CD47中和的心脏保护作用及心脏成纤维细胞清除。
临床怎么用
- CD47可作为DoxCM的疾病特异性治疗靶点进行进一步临床转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Doxorubicin cardiomyopathy (DoxCM) remains a significant clinical problem, but its underlying mechanisms remain incompletely understood. Identifying DoxCM mechanisms can lead to therapeutic interventions that improve patient outcomes. METHODS: We performed single-nucleus RNA sequencing on left ventricular myocardial tissue from patients with DoxCM versus nonischemic cardiomyopathy and nonfailing donors. This approach aimed to uncover the transcriptional changes associated with DoxCM. Additionally, we conducted immunostaining, flow cytometry, antibody neutralization, and cell depletion studies to validate our findings and define in vivo mechanisms. RESULTS: Compared with nonfailing donors and patients with nonischemic cardiomyopathy, left ventricular myocardium from patients with DoxCM exhibited increased POSTN (periostin)+ activated fibroblasts, downregulation of genes involved in phagocytosis, and increased expression of the antiphagocytic molecule CD47. Immunostaining of human cardiac sections and murine studies demonstrated increased POSTN+ cells and CD47 in DoxCM and in a murine breast cancer model. CD47 antibody neutralization both prevented and treated doxorubicin-induced reduction in left ventricular ejection fraction and fibrosis. Mechanistically, depletion of resident cardiac macrophages blocked the cardioprotective effects of CD47 neutralization and clearance of cardiac fibroblasts. CONCLUSIONS: Our data support CD47 as a disease-specific target and promising therapeutic approach for mitigating cardiac dysfunction in DoxCM.
引用
- Guo Z, Ataran A, Ma P, et al. Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy. Circulation. 2025. PMID: 40808662. doi:10.1161/CIRCULATIONAHA.124.071217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。